// App-Quantinova.ai

29 : Lung-MAP composite signature for immune checkpoint inhibitor (ICI) efficacy in advanced squamous cell lung cancer (SCC)

Researchers

Presenter

  • David Gandara

Principal Investigators

  • Xing Hua

  • Khaled Tolba

  • David Fabrizio

  • Lee Albacker

  • Ryan Brennick

  • Meagan Montesion

  • Geoff Oxnard

  • Stacey Adam

  • Fred Hirsch

  • Karen Kelly

  • Roy Herbst

  • Michael Leblanc

  • Mary Redman

  • Michael Wu

  • David Kozono

Medical Centers

  • Brigham and Women’s Hospital, Boston, MA, USA

  • Foundation for the NIH, North Bethesda, MD

  • University of California, Davis Medical Center, Sacramento, CA

  • Fred Hutchinson Org, Seattle, WA, USA

  • Mount Sinai Health Systems, New York, NY

  • International Association for the Study, Denver, CO, USA

  • Yale School of Medicine, NEW HAVEN, CT, USA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Lung Cancer

  • Non Small Cell Lung cancer

Biomarkers

  • AT-rich interactive domain 1A

  • Cyclin Dependent Kinase Inhibitor 2A

  • Programmed death-ligand 1

  • Kelch Like ECH Associated Protein 1

  • Serpin B3

  • Tumor mutational burden

Drug/Treatment

  • Durvalumab

  • Ipilimumab

  • Nivolumab

  • SP263

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved